Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) insider Family Fund Couchman purchased 950,623 shares of the stock in a transaction that occurred on Monday, January 7th. The stock was purchased at an average price of $0.24 per share, for a total transaction of $228,149.52. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of OTCMKTS:ENZN opened at $0.26 on Friday. Enzon Pharmaceuticals Inc has a one year low of $0.20 and a one year high of $0.30.
TRADEMARK VIOLATION NOTICE: “Enzon Pharmaceuticals Inc (ENZN) Insider Purchases $228,149.52 in Stock” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2019/01/12/enzon-pharmaceuticals-inc-enzn-insider-purchases-228149-52-in-stock.html.
Enzon Pharmaceuticals, Inc, together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
See Also: How Investors Use a Balance Sheet
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.